GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Grace Therapeutics Inc (NAS:GRCE) » Definitions » Cyclically Adjusted Book per Share

GRCE (Grace Therapeutics) Cyclically Adjusted Book per Share : $39.22 (As of Dec. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Grace Therapeutics Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Grace Therapeutics's adjusted book value per share for the three months ended in Dec. 2024 was $5.142. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $39.22 for the trailing ten years ended in Dec. 2024.

During the past 12 months, Grace Therapeutics's average Cyclically Adjusted Book Growth Rate was -28.20% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -1.00% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 2.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Grace Therapeutics was 6.70% per year. The lowest was -1.00% per year. And the median was 4.50% per year.

As of today (2025-05-14), Grace Therapeutics's current stock price is $2.7306. Grace Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2024 was $39.22. Grace Therapeutics's Cyclically Adjusted PB Ratio of today is 0.07.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Grace Therapeutics was 0.94. The lowest was 0.03. And the median was 0.06.


Grace Therapeutics Cyclically Adjusted Book per Share Historical Data

The historical data trend for Grace Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grace Therapeutics Cyclically Adjusted Book per Share Chart

Grace Therapeutics Annual Data
Trend Feb14 Feb15 Feb16 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 50.00 53.68 58.39 60.72 52.13

Grace Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 54.61 52.13 48.06 43.48 39.22

Competitive Comparison of Grace Therapeutics's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Grace Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Grace Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Grace Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Grace Therapeutics's Cyclically Adjusted PB Ratio falls into.


;
;

Grace Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Grace Therapeutics's adjusted Book Value per Share data for the three months ended in Dec. 2024 was:

Adj_Book= Book Value per Share /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=5.142/133.1571*133.1571
=5.142

Current CPI (Dec. 2024) = 133.1571.

Grace Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201411 139.769 99.635 186.795
201502 120.172 99.032 161.582
201505 117.212 100.333 155.559
201508 106.063 100.548 140.461
201511 97.806 100.135 130.061
201602 90.076 100.040 119.895
201605 82.969 101.355 109.002
201608 75.399 101.617 98.802
201611 65.987 101.829 86.288
201706 47.531 103.349 61.240
201709 38.876 104.136 49.710
201712 23.431 104.011 29.997
201803 11.925 105.290 15.081
201806 7.512 106.317 9.408
201809 -15.018 106.507 -18.776
201812 13.811 105.998 17.350
201903 6.784 107.251 8.423
201906 1.650 108.070 2.033
201909 -0.710 108.329 -0.873
201912 -2.582 108.420 -3.171
202003 6.915 108.902 8.455
202006 5.727 108.767 7.011
202009 4.397 109.815 5.332
202012 7.907 109.897 9.581
202103 12.822 111.754 15.278
202106 12.314 114.631 14.304
202109 15.473 115.734 17.802
202112 15.047 117.630 17.033
202203 14.669 121.301 16.103
202206 14.078 125.017 14.995
202209 13.472 125.227 14.325
202212 13.009 125.222 13.833
202303 9.140 127.348 9.557
202306 8.608 128.729 8.904
202309 7.101 129.860 7.281
202312 6.882 129.419 7.081
202403 6.569 131.776 6.638
202406 5.854 132.554 5.881
202409 5.536 133.029 5.541
202412 5.142 133.157 5.142

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Grace Therapeutics  (NAS:GRCE) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Grace Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=2.7306/39.22
=0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Grace Therapeutics was 0.94. The lowest was 0.03. And the median was 0.06.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Grace Therapeutics Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Grace Therapeutics's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Grace Therapeutics Business Description

Industry
Traded in Other Exchanges
N/A
Address
103 Carnegie Center, Suite 300, Princeton, NJ, USA, 08540
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.
Executives
George Kottayil director 49 OLD BEAR BROOK ROAD, PRINCETON NJ 08540
A Brian Davis director C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Edward Neugeboren director 282 NEW NORWALK ROAD, NEW CANAAN CT 06840
Vimal Kavuru director 11 MAACKA DRIVE, HOLMDEL NJ 07733
Donald Olds director 545 PROMENADE DU CENTROPOLIS, SUITE 100, LAVAL A8 H7T 0A3
Amresh Kumar officer: VP Program Management 3009, BOUL. DE LA CONCORDE EAST, SUITE 102, LAVAL A8 H7E 2B5
Carrie D'andrea officer: VP Clinical Operations 3009, BOUL. DE LA CONCORDE EAST, SUITE 102, LAVAL A8 H7E 2B5
Prashant Kohli officer: Chief Executive Officer 206 CAMBRIDGE LANE, NEWTOWN PA 13940
R. Loch Macdonald officer: Chief Medical Officer 200 CONNELL DRIVE, SUITE 1600, BERKELEY HEIGHTS NJ 07922
Michael Derby director 303 SOUTH BROADWAY, SUITE 125, TARRYTOWN NY 10591
William A Haseltine director
Rajitha Grace 2018 Irrevocable Trust 10 percent owner 40 BEY LEA ROAD, SUITE C 202, TOMS RIVER NJ 08753
Swami Sambamurty Iyer 10 percent owner 20 TULSA COURT, MONMOUTH JUNCTION NJ 08852
Brian D. Ford officer: CHIEF FINANCIAL OFFICER 3009, BOUL. DE LA CONCORDE EAST, SUITE 102, LAVAL A8 H7E 2B5
John Canan director C/O REV GROUP, INC., 111 EAST KILBOURN AVENUE, SUITE 2600, MILWAUKEE WI 53202